The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients’ survival: a meta-analysis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients’ survival: a meta-analysis
Authors
Keywords
MGMT, Meta-analysis, Glioblastoma, Hazard ratio, Pyrosequencing, Survival, Prognostic biomarker
Journal
World Journal of Surgical Oncology
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-10-12
DOI
10.1186/s12957-016-1012-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- The Role of Molecular Diagnostics in the Management of Patients with Gliomas
- (2016) Hans-Georg Wirsching et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
- (2015) M. Weller et al. CLINICAL CANCER RESEARCH
- Clinical impact of molecular biomarkers in gliomas
- (2015) Tali Siegal JOURNAL OF CLINICAL NEUROSCIENCE
- TheMGMTpromoter SNP rs16906252 is a risk factor forMGMTmethylation in glioblastoma and is predictive of response to temozolomide
- (2015) Robert W. Rapkins et al. NEURO-ONCOLOGY
- Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients
- (2014) Véronique Quillien et al. JOURNAL OF NEURO-ONCOLOGY
- MGMT Promoter Methylation Correlates with an Overall Survival Benefit in Chinese High-Grade Glioblastoma Patients Treated with Radiotherapy and Alkylating Agent-Based Chemotherapy: A Single-Institution Study
- (2014) Dong Shen et al. PLoS One
- Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial
- (2014) Vincent Peter Collins et al. Acta Neuropathologica Communications
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma
- (2013) Matthias Preusser et al. CLINICAL NEUROPATHOLOGY
- Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome
- (2013) Shadi Lalezari et al. NEURO-ONCOLOGY
- IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta-Analysis
- (2013) Peng Zou et al. PLoS One
- Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g
- (2012) Véronique Quillien et al. CANCER
- Clinical neuropathology practice guide 06-2012: MGMT testing in elderly glioblastoma patients yes, but how?
- (2012) Anna S. Berghoff et al. CLINICAL NEUROPATHOLOGY
- Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
- (2012) Annika Malmström et al. LANCET ONCOLOGY
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
- (2012) Wolfgang Wick et al. LANCET ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009
- (2012) T. A. Dolecek et al. NEURO-ONCOLOGY
- Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma
- (2011) Miyuki Uno et al. Clinics
- Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
- (2011) Guido Reifenberger et al. INTERNATIONAL JOURNAL OF CANCER
- MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations
- (2011) Shani Mulholland et al. INTERNATIONAL JOURNAL OF CANCER
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
- (2010) Houtan Noushmehr et al. CANCER CELL
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy
- (2009) J Dunn et al. BRITISH JOURNAL OF CANCER
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
- (2009) Michael Weller et al. Nature Reviews Neurology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search